Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of Hylatopic Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.

Hylatopic Emollient Foam is formulated to rapidly hydrate the stratum corneum, the top layer of the skin, and immediately provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis. Hylatopic is clinically proven to rapidly increase skin hydration and reduce transepidermal water loss, supporting the skin's natural recovery from skin barrier dysfunction to optimize therapeutic outcomes.

Hylatopic is safe and easy to spread over large areas and therefore is ideal for atopic dermatitis patients with disease coverage on greater than 10 per cent body surface area (BSA). The company's recent market research with dermatologists indicates that 70 per cent or more of their patients may have atopic dermatitis present on at least 10 per cent of their body. Developed with the company's Delevo Foam Technology, Hylatopic is cosmetically elegant, contains no drying alcohols, is absorbed rapidly, and leaves no oily or sticky residue.

"We are very excited to be able to offer Hylatopic to our physicians and patients," states Michael Heffernan, president of Onset Therapeutics. "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. Hylatopic's 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes."

Hylatopic Emollient Foam is currently available through all major drug wholesalers.

Atopic dermatitis is a disease characterized by dry, cracked, itchy, and inflamed skin, often presenting on greater than 10 per cent of the body surface area. It accounts for 10-20 per cent of all Dermatology visits and affects approximately 3 per cent of the US population, 90 per cent of whom develop symptoms by age 53. The compromised skin barrier in atopic dermatitis patients allows excessive water loss through the epidermal layer of the skin and penetration of potential allergens.

Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the company's innovative proprietary topical formulation technologies and unique delivery systems.